SCHEMBL1879178

SCHEMBL1879178

CCOC(=O)C=CC(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.56
MAPT P10636 5/20 0.46
NPSR1 Q6W5P4 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
ALDH1A1 P00352 3/20 0.41
ATM Q13315 1/20 0.40
TTR P02766 1/20 0.40
DPP4 P27487 1/20 0.40
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
MDM2 Q00987 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594049 1.00 HCAR2 (0.56) HCAR2MAPTNPSR1CA12CA1
SCHEMBL23666175 0.84 HCAR2 (0.54) HCAR2MAPTNPSR1CA12CA1
SCHEMBL30873909 0.83 HCAR2 (0.52) HCAR2MAPTNPSR1CA12CA1
SCHEMBL1886588 0.83 HCAR2 (0.59) HCAR2MAPTNPSR1ALDH1A1ATM
SCHEMBL17285584 0.83 HCAR2 (0.52) HCAR2MAPTNPSR1CA12CA1
SCHEMBL22428831 0.83 HCAR2 (0.52) HCAR2MAPTNPSR1CA12CA1
SCHEMBL4184914 0.81 HCAR2 (0.50) HCAR2MAPTNPSR1CA12CA1
SCHEMBL17518625 0.81 HCAR2 (0.50) HCAR2MAPTNPSR1CA12CA1
SCHEMBL4194175 0.81 HCAR2 (0.50) HCAR2MAPTNPSR1CA12CA1
SCHEMBL4194178 0.81 HCAR2 (0.50) HCAR2MAPTNPSR1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108586272-A A kind of preparation method of 3- aminopropanols or 3- alanine derivatives 浙江昌明药业有限公司 2018-09-28 CN disclosed
US-9925204-B2 Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation KAWAI TOSHIHISA (US) 2018-03-27 US disclosed
US-9545415-B2 Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation SKYVIEW ENTPR LTD (US) 2017-01-17 US disclosed
US-20160317575-A1 ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION KAWAI TOSHIHISA (US) 2016-11-03 US disclosed
US-20150140090-A1 ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION SKYVIEW ENTPR LTD (US) 2015-05-21 US disclosed
EP-0934061-B3 ISOBUTYLGABA AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN WARNER LAMBERT CO (US) 2015-01-21 EP disclosed
EP-1666440-B1 METHOD FOR PRODUCING AROMATIC UNSATURATED COMPOUND SUMITOMO CHEMICAL CO (JP) 2014-01-22 EP disclosed
WO-2013103826-A1 ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION SKYVIEW ENTERPRISE LTD. (US) 2013-07-11 WO disclosed
EP-2013171-B1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER S DISEASE MERCK SHARP & DOHME (GB) 2013-05-15 EP disclosed
US-8389547-B2 Piperidines and related compounds for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2013-03-05 US disclosed
WO-1998003167-A1 ISOBUTYLGABA AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN WARNER-LAMBERT COMPANY (US) 1998-01-29 WO disclosed
US-5710304-A 5-METHYL-3((((4-METHYLPHENYL)SULFONYL)OXY)-METHYL)-HEXANOIC ACID ESTER CHEMICAL INTERMEDIATES NORTHWESTERN UNIVERSITY (US) 1998-01-20 US disclosed
US-5684189-A HYDROLYZING AN AZIDE TO FORM AN INTERMEDIATE AZIDE, EXTRACTING THE INTERMEDIATE AZIDE INTO AN AQUEOUS BASE AND REDUCING THE AZIDE TO AN AMINE NORTHWESTERN UNIVERSITY (US) 1997-11-04 US disclosed
EP-0641330-A4 GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT. UNIV NORTHWESTERN (US) 1997-05-28 EP disclosed
US-5608090-A ANTICONVULSANTS NORTHWESTERN UNIVERSITY (US) 1997-03-04 US disclosed
US-5599973-A REACTING ACID CHLORIDE WITH SUBSTITUTED 2-OXAZOLIDINONE AND BUTYLLITHIUM, THEN BENZYL ALPHA-BROMOACETATE, HYDROGEN PEROXIDE, LITHIUM OXIDE, SODIUM METABISULFITE, BORANE DIMETHYL SULFIDE, THEN TOSYLATION, AZIDE FORMATION, AMINATION NORTHWESTERN UNIVERSITY (US) 1997-02-04 US disclosed
US-5563175-A GAMMAAMINOBUTYRIC ACID DERIVATIVE; NERVOUS SYSTEM DISORDERS NORTHWESTERN UNIVERSITY (US) 1996-10-08 US disclosed
EP-0641330-A1 GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT NORTHWESTERN UNIVERSITY (US) 1995-03-08 EP disclosed
WO-1993023383-A1 GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT NORTHWESTERN UNIVERSITY (US) 1993-11-25 WO disclosed
WO-1992009560-A1 GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT NORTHWESTERN UNIVERSITY (US) 1992-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160317575-A1 ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION PTGS1, HVCN1, HRH2 HCAR2 17/4885MAPT 1000/4885NPSR1 915/4885
US-20150140090-A1 ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION PTGS1, HVCN1, HRH2 HCAR2 17/4885MAPT 1000/4885NPSR1 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.